ポスターダウンロード_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

top

Please input keywords

ニュース&PR

お問い合わせ

JP

私たちの歩み

管理スタッフ

社会的責任

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

動物・細胞モデル

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology service

Therapeutic area

Types of services

ゲノム編集

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

資料ダウンロード

ポスターダウンロード

ニュース & PR

世界に通用する跳躍

ニュースリリース

キャンペーン一覧

ウェビナー

発表論文一覧

資料ダウンロード

ポスターダウンロード

製品資料ダウンロード

AACR 2025: Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC)

AACR 2025: A novel PD-1, IL12Rβ1 and IL12Rβ2 humanized mouse model for evaluating the combined efficacy of anti-tumor therapies

AACR 2025: A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical toxicity evaluation of human IL-12 analogs

AACR 2025: Humanized GDF15 model for simulating weight loss induced by GDF15 secretion in tumors

AACR 2025: Animal models for evaluating the efficacy of anti-human HER2 ADC alone or in combination with IO therapy

AACR 2025: Development of TNFR2, TNFR1 and LTBR humanized mouse model for evaluating anti-human LTBR antibodies

AACR 2025: Preclinical evaluation of CD3/DLL3 bispecific antibody in syngeneic and humanized mouse models for solid tumor treatment

AACR 2025: Preclinical syngeneic model and xenograft model for evaluating CD3/HER2 bispecific antibody therapy

AACR 2025: A novel humanized IL2 and IL15 receptor mouse model enables preclinical efficacy studies for IL-2 cancer therapeutics

1 2 3 4 5 … 14